Merck (MRK) initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX(TM) (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
Importance
Level 1
#GERMANY#EUROPE#MERCK & CO INC#MRK.US#MERCK KGAA#TOYOTA MOTOR CORP#TM.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DAX 40 INDEX#MRK#GLOBAL NEWS